Some answers to your questions.... 1) Sanguine has done transfusion work in the Japanese,Canadian, British, German populatons and with the Jehovah's Witnesses, totalling thousands of patients. You can find the specifics onthe info thread. 2) The side effects attributed to Fluosol was due to the emulsion used to keep the Fluosol molecules from clumping....that problem has been worked out since subsequent data showed no incidence of embolism, allergic reactions, etc.Again, this info is all on the info thread. Regardless of how long it took to approve Fluosol for angioplasties, pher02 should not take as long to be approved for trauma, surgical and chronic transfusion indications. My best GUESS would be three years. 3)I am not sure what you mean by "the existing market." If you mean angioplasty, you may be right.However, the main use will be in transfusion situations and for heart-bypass machines .When you consider that the transfusion market is tens of billions of dollars a year , and pher02 will cost about 10% of a pint of blood($30vs. $300 for a pint of blood), I would say that the profit margin will be quite fine for Sanguine once Pher02 hits the market for transfusion use. Don't forget that the other uses would generate additional revenue.BTW, the first approval is to be for heart-bypass machines, a market in which about 300,000 procedures are done in the US yearly.
|
